Cipla (NSE:CIPLA, BOM:500087) received seven observations in Form 483 from the U.S. Food and Drug Administration after a follow-up current good manufacturing practices inspection of its manufacturing facility in Pithampur, India.
The regulator inspected the Pithampur facility from Aug. 17 to Aug. 25, the pharmaceutical company said in a Tuesday filing with the Indian bourses.
Cipla said it will work closely with the U.S. FDA to address the observations within the stipulated timeline.